Hospital Practices and Research

Abstract Amacher and colleagues have assembled a dataset and posed exactly the right question: not merely whether women and men differ in how often life-sustaining therapy is curtailed, but when along the care pathway that divergence takes shape. Their headline finding is elegant in its symmetry. A pronounced female excess at admission (adjusted odds ratio 1.26, 95% CI 1.24–1.28) gives way, they report, to parity once treatment is under way, the during-stay rates standing at “5.5% versus 5.5%.” From this they infer that decisions grow more even-handed as objective clinical information accrues. We admire the study but believe two linked problems undermine that inference. The first is arithmetical and present on the face of Table 1; the second is structural and inheres in the staged design itself. Both deserve closer scrutiny than they have so far received.

Abstract Despite remarkable advances in reperfusion strategies, antithrombotic therapy, and secondary prevention, myocardial infarction (MI) remains a leading cause of heart failure and cardiovascular mortality worldwide. Among emerging regenerative approaches, exosome engineering has attracted considerable scientific interest. Exosomes are nano-sized extracellular vesicles secreted by nearly all cell types and are now recognized as highly organized mediators of intercellular communication. By transporting microRNAs, proteins, lipids, and signaling molecules, exosomes influence gene expression and cellular behavior in target tissues. We argue that integrating metabolic modulators with engineered exosome delivery platforms represents not merely an incremental innovation but a paradigm shift in post-MI regenerative therapy.